UK Risks Becoming ‘Economically Unviable’ For Biosimilars
BGMA Report Warns Over VPAS Impact And Calls For National Biosimilars Strategy
Amid increasing financial pressure from the VPAS rebate scheme and a lack of a national uptake strategy, the BGMA has warned that the UK risks losing its leading position in European biosimilars and could become altogether “economically unviable” for biosimilars suppliers.
